Evidence map›Paper›PMID 21738637›Full record

ArticlePloS one2011

Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).

Nitish Agrawal, Daniel P Leaman, Eric Rowcliffe, Heather Kinkead, Raman Nohria, Junya Akagi, Katherine Bauer, Sean X Du, Robert G Whalen, Dennis R Burton and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nitish AgrawalDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America.
Daniel P Leaman
Eric Rowcliffe
Heather Kinkead
Raman Nohria
Junya Akagi
Katherine Bauer
Sean X Du
Robert G Whalen
Dennis R Burton
Michael B Zwick
Scripps Research Institute · USAltravax (United States) · US

Funding

Viral Neutralization AssaysP01AI056375 · NIAID · MAXYGEN, INC. · PI WHALEN, ROBERT G. · 2005 to 2009
$11.1M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR01AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 1992 to 2013
$5.9M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR37AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1995 to 2004
$2.4M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007606 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1999 to 2013
$2.1M
Engineering and sorting HIV-1 display Env libraries for vaccine designR33AI077381 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2011 to 2013
$1.7M
Engineering and sorting HIV-1 display Env libraries for vaccine designR21AI077381 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2008 to 2009
$517k
NIAID NIH HHS AI33292NIAID NIH HHS AI56375NIAID NIH HHS AI77381NIAID NIH HHS P01 AI056375NIAID NIH HHS R01 AI033292NIAID NIH HHS R21 AI077381NIAID NIH HHS R33 AI077381NIAID NIH HHS R37 AI033292NIAID NIH HHS T32 AI007606
6 · The paper itself

Abstract

The HIV-1 envelope glycoprotein (Env) spike is challenging to study at the molecular level, due in part to its genetic variability, structural heterogeneity and lability. However, the extent of lability in Env function, particularly for primary isolates across clades, has not been explored. Here, we probe stability of function for variant Envs of a range of isolates from chronic and acute infection, and from clades A, B and C, all on a constant virus backbone. Stability is elucidated in terms of the sensitivity of isolate infectivity to destabilizing conditions. A heat-gradient assay was used to determine T(90) values, the temperature at which HIV-1 infectivity is decreased by 90% in 1 h, which ranged between ∼40 to 49°C (n = 34). For select Envs (n = 10), the half-lives of infectivity decay at 37°C were also determined and these correlated significantly with the T(90) (p = 0.029), though two 'outliers' were identified. Specificity in functional Env stability was also evident. For example, Env variant HIV-1(ADA) was found to be labile to heat, 37°C decay, and guanidinium hydrochloride but not to urea or extremes of pH, when compared to its thermostable counterpart, HIV-1(JR-CSF). Blue native PAGE analyses revealed that Env-dependent viral inactivation preceded complete dissociation of Env trimers. The viral membrane and membrane-proximal external region (MPER) of gp41 were also shown to be important for maintaining trimer stability at physiological temperature. Overall, our results indicate that primary HIV-1 Envs can have diverse sensitivities to functional inactivation in vitro, including at physiological temperature, and suggest that parameters of functional Env stability may be helpful in the study and optimization of native Env mimetics and vaccines.

Indexed as

Electrophoresis, Polyacrylamide Gelenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunosorbent AssayHEK293 CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HIV Reverse TranscriptaseHumansTemperatureenv Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp120HIV Envelope Protein gp41HIV Reverse Transcriptasereverse transcriptase, Human immunodeficiency virus 1

Identifiers

PMID21738637
PMCPMC3124497
OpenAlexW2040109424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.